DS

Diwan Singh

Active Director Director DIN 08333549
DIN 08333549 First appointment Jan 2019 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Jan 2019
Shareholding value •••• Premium profile

About Diwan Singh

Data last updated:

Diwan Singh is a Director at Rayford Pharmaceutical Private Limited (since 2019). The company operates in Pharma. Rayford Pharmaceutical Private Limited reported revenue of ₹5.5 Lakh (FY 2021).

DIN 08333549
Primary Designation Director
Industry Pharma
First Appointment 16 Jan 2019
Oldest Company Age 7 yrs
Largest company Rayford Pharmaceutical Private Limited · ₹5.5 Lakh (FY 2021)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director16 Jan 20192019₹5.5 Lakh (FY 2021)Active

Directorship timeline

Open interactive timeline →
Rayford Pharmaceutical Private Limited
Premium access

Shareholding and investment profile for Diwan Singh

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Diwan Singh

Diwan Singh currently holds 1 directorship: Rayford Pharmaceutical Private Limited (Director, since 16 Jan 2019, revenue ₹5.5 Lakh (FY 2021)).

Diwan Singh was first appointed on 16 Jan 2019 as Director at Rayford Pharmaceutical Private Limited.

The current boards of Diwan Singh's companies include Devendra Singh (Rayford Pharmaceutical Private Limited), Vijaypal Singh (Rayford Pharmaceutical Private Limited), Vinod Purswaney (Rayford Pharmaceutical Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available